Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2004 2
2005 2
2006 5
2007 2
2008 1
2009 3
2010 5
2011 6
2012 3
2013 1
2014 6
2015 6
2016 5
2017 2
2018 4
2019 9
2020 8
2021 9
2022 10
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide does not interfere with OATP-mediated uptake of docetaxel.
Buck SAJ, Talebi Z, Drabison T, Jin Y, Gibson AA, Hu P, de Bruijn P, de Ridder CMA, Stuurman D, Hu S, van Weerden WM, Koolen SLW, de Wit R, Sparreboom A, Mathijssen RHJ, Eisenmann ED. Buck SAJ, et al. Among authors: van weerden wm. Int J Cancer. 2024 Mar 16. doi: 10.1002/ijc.34922. Online ahead of print. Int J Cancer. 2024. PMID: 38491867
Defining the challenges and opportunities for using patient-derived models in prostate cancer research.
Brennen WN, Le Magnen C, Karkampouna S, Anselmino N, Bock N, Choo N, Clark AK, Coleman IM, Dolgos R, Ferguson AM, Goode DL, Krutihof-de Julio M, Navone NM, Nelson PS, O'Neill E, Porter LH, Ranasinghe W, Sunada T, Williams ED, Butler LM, Corey E, van Weerden WM, Taylor RA, Risbridger GP, Lawrence MG. Brennen WN, et al. Among authors: van weerden wm. Prostate. 2024 May;84(7):623-635. doi: 10.1002/pros.24682. Epub 2024 Mar 7. Prostate. 2024. PMID: 38450798 Free article. Review.
Capivasertib combines with docetaxel to enhance anti-tumour activity through inhibition of AKT-mediated survival mechanisms in prostate cancer.
Eberlein C, Williamson SC, Hopcroft L, Ros S, Moss JI, Kerr J, van Weerden WM, de Bruin EC, Dunn S, Willis B, Ross SJ, Rooney C, Barry ST. Eberlein C, et al. Among authors: van weerden wm. Br J Cancer. 2024 May;130(8):1377-1387. doi: 10.1038/s41416-024-02614-w. Epub 2024 Feb 23. Br J Cancer. 2024. PMID: 38396173 Free PMC article.
Darolutamide Added to Docetaxel Augments Antitumor Effect in Models of Prostate Cancer through Cell Cycle Arrest at the G1-S Transition.
Buck SAJ, Van Hemelryk A, de Ridder C, Stuurman D, Erkens-Schulze S, van 't Geloof S, Teubel WJ, Koolen SLW, Martens-Uzunova ES, van Royen ME, de Wit R, Mathijssen RHJ, van Weerden WM. Buck SAJ, et al. Among authors: van weerden wm. Mol Cancer Ther. 2024 May 2;23(5):711-720. doi: 10.1158/1535-7163.MCT-23-0420. Mol Cancer Ther. 2024. PMID: 38030379
The future of patient-derived xenografts in prostate cancer research.
Lawrence MG, Taylor RA, Cuffe GB, Ang LS, Clark AK, Goode DL, Porter LH, Le Magnen C, Navone NM, Schalken JA, Wang Y, van Weerden WM, Corey E, Isaacs JT, Nelson PS, Risbridger GP. Lawrence MG, et al. Among authors: van weerden wm. Nat Rev Urol. 2023 Jun;20(6):371-384. doi: 10.1038/s41585-022-00706-x. Epub 2023 Jan 17. Nat Rev Urol. 2023. PMID: 36650259 Free PMC article. Review.
Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling.
Van Hemelryk A, Tomljanovic I, de Ridder CMA, Stuurman DC, Teubel WJ, Erkens-Schulze S, Verhoef EI, Remmers S, Mahes AJ, van Leenders GJLH, van Royen ME, van de Werken HJG, Grudniewska M, Jenster GW, van Weerden WM. Van Hemelryk A, et al. Among authors: van weerden wm. Cells. 2022 Nov 16;11(22):3632. doi: 10.3390/cells11223632. Cells. 2022. PMID: 36429059 Free PMC article.
86 results